Taylor & Francis Group

SHERPA: Unknown

People

  1. Park
    Park
  2. Geyer
    Geyer
  3. Tallman
    Tallman
  4. Derkach
    Derkach
  5. Arcila
    Arcila
  6. Aypar
    Aypar
  7. Borge
    Borge
  8. Chin
    Chin
  9. Daley
    Daley
  10. Dogan
    Dogan

Groups

  1. Adult Leukemia (12)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (12)
  4. Hematologic Malignancies, Division of (12)
  5. Hematology-Oncology Fellows (5)
  6. Weinberg Fellows (5)
  7. Advanced Practice Providers (2)
  8. Biostatistics Service (2)
  9. Department of Pathology and Laboratory Medicine (2)
  10. Epidemiology and Biostatistics (2)
Search Within
  1. "Jae Park"
Formats
  1. Journal Article (6)
  2. Review (4)
  3. Correspondence (1)
  4. Meeting Abstract (1)
Groups
  1. Adult Leukemia (12)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (12)
  4. Hematologic Malignancies, Division of (12)
  5. Hematology-Oncology Fellows (5)
  6. Weinberg Fellows (5)

More Groups

People
  1. Jae Park (12)
  2. Mark Geyer (5)
  3. Martin Tallman (5)
  4. Andriy Derkach (2)
  5. Lindsey Roeker (2)
  6. Aaron Goldberg (1)

More People

Years
  1. 2025 (3)
  2. 2023 (1)
  3. 2021 (1)
  4. 2020 (4)
  5. 2018 (1)
  6. 2014 (1)

More Years

Publications
  1. Leukemia and Lymphoma (9)
  2. Expert Review of Hematology (3)

Results (12)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: A plain language summary
    Review

    Marks, D. I.; Cassaday, R. D.; Ribera, J. M.; Schuh, A. C.; Park, J. H.; Chiaretti, S.; Stelljes, M.
    Expert Review of Hematology (2025)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: A systematic literature review
    Review

    Marks, D. I.; Cassaday, R. D.; Ribera, J. M.; Schuh, A. C.; Park, J. H.; Chiaretti, S.; Stelljes, M.
    Expert Review of Hematology (2025)

    Fulltext@MSK | Save
  • Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: A review
    Review

    Locatelli, F.; Shah, B.; Thomas, T.; Velasco, K.; Adedokun, B.; Aldoss, I.; Gore, L.; Hoelzer, D.; Bassan, R.; Park, J. H.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia
    Journal Article

    Daley, R. J.; Rajeeve, S.; Kabel, C. C.; Pappacena, J. J.; Stump, S. E.; Lavery, J. A.; Tallman, M. S.; Geyer, M. B.; Park, J. H.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: From basic to practice
    Review

    Wudhikarn, K.; Park, J. H.
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naïve acute lymphoblastic leukemia
    Correspondence

    Gaulin, C.; Chan, A.; Derkach, A.; Park, J. H.; Mantha, S.; Geyer, M. B.; Tallman, M. S.
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Phase I/II triple therapy study of umbralisib and ublituximab ("U2") combined with checkpoint inhibition in patients with rel/ref CLL and Richter's transformation
    Meeting Abstract

    Mato, A.; Svoboda, J.; Luning-Prak, E.; Schuster, S.; Tsao, P.; Dorsey, C.; Sarmasti, L.; Becker, P.; Brander, D.; Geyer, M.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Clonally-related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications
    Journal Article

    Kumar, P.; Uppal, M.; Xiao, W.; Dogan, A.; Roshal, M.; Gao, Q.; Aypar, U.; Zhang, Y.; Arcila, M. E.; Moung, C.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells
    Journal Article

    Geyer, M. B.; Manjunath, S. H.; Evans, A. G.; Park, J. H.; Davila, M. L.; Cutler, C. S.; Wang, X.; Wang, Y.; Senechal, B.; Rivière, I.; more...
    Leukemia and Lymphoma (2018)

    Fulltext@MSK | Save